Axl inhibitors as novel cancer therapeutic agents

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Axl receptor tyrosine kinase (RTK) overexpression is linked to cancer cell proliferation, invasion, metastasis, and chemotherapy resistance.
• Axl is a key member of the TAM (Tyro3, Axl, Mer) receptor tyrosine kinase family.
• Dysregulation of Axl signaling is implicated in various human cancers, including lung, breast, and pancreatic cancers.

Purpose of the Study:

• To provide an updated review of Axl inhibitors.
• To explore the latent therapeutic applications of Axl inhibitors in cancer treatment.
• To highlight the potential of targeting Axl to overcome drug resistance and improve patient outcomes.

Main Methods:

• Literature review of recent studies on Axl inhibitors.
• Analysis of the mechanisms of action for different Axl inhibitors.
• Evaluation of preclinical and clinical data on Axl-targeted therapies.

Main Results:

• Axl inhibitors can effectively block kinase signaling nodes driven by Axl.
• Targeting Axl has shown potential in restoring sensitivity to chemotherapy in resistant cancer models.
• Emerging data suggest Axl inhibitors may enhance the efficacy of existing cancer therapies.

Conclusions:

• Axl receptor tyrosine kinase is a critical therapeutic target in oncology.
• Axl inhibitors represent a promising class of drugs for managing advanced cancers.
• Further investigation into Axl inhibitors is warranted to optimize their clinical application and improve patient survival.